Drugs / Drotaverine
Drotaverine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01236651 | Nov 2010 → Apr 2011 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00731198 | Aug 2008 → Mar 2009 | bile duct disorder, pancreas disorder | Changhai Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00292747 | May 2005 → Feb 2006 | dysmenorrhea | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01639027 Comparator | May → Dec 2012 | cervix disorder, perinatal asphyxia | Ain Shams Maternity Hospital | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drotaverine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01236651 ↗ |
| Known as | Do-Spa | “to make the yellowish colored Drotaverine Hydrochloride (Do-Spa®) in-differentiable from the translucent saline solution.” NCT01639027 ↗ |
| Known as | Drotaverin | ChEMBL registry synonym — accepted as the source's own label CHEMBL551978 ↗ |
| Known as | Drotaverina | ChEMBL registry synonym — accepted as the source's own label CHEMBL551978 ↗ |
| Known as | Drotaverine Hydrochloride | “Each participant will randomly take a prefilled syringe with two milliliters of the study medication solution (either Drotaverine Hydrochloride or saline).” NCT01639027 ↗ |
| Known as | Drotin | ChEMBL registry synonym — accepted as the source's own label CHEMBL551978 ↗ |
| Action | Inhibit | “selectively inhibits phosphodiesterase IV” NCT00731198 ↗ |
| Modality | Small molecule | “Drotaverine, an isoquinolone derivative” NCT01639027 ↗ |
| Route | Oral | “Drotaverine 80 mg plus ibuprofen placebo orally” NCT00292747 ↗ |